chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had 5 vaccines on 10/27/08.  Today 10/29/08 saw MD d/t R deltoid area with 7.5cm x 7.5cm redness and 7cm X 9cm induration.  No fever or drng from site.  In R arm had Menactra, Boosterix, and Varivax.
Our son got the booster for Tdap on Wednesday Aug 21st. The next morning he had a large rash on his arm. He also had flu like symptoms. Today he has dark yellow mucous and runny nose and cough. We are very concerned. We are taking him to urgent care however we need to follow up since he keeps having issues with the vaccines. As mentioned at the appointment he had large lymph nodes with the MMR vaccine prior to this one. Please have th someone contact us ASAP. Thank you.
Nausea, 38.9C fever, chills, muscle pain, headache, trigeminal neuralgia, dizziness, vertigo and fullness in ear. I took an ibuprofen twice and felt better. The symptoms went away in 24 hours since they started with the exception of dizziness, vertigo and neuralgia that still persists (this is the 6th day from the vaccine).  I tried Excedrin , ibuprofen, magnesium for these  symptoms and have no  relief or improvement.
This case was reported by a other health professional via sales rep and described the occurrence of rash in a 89-year-old female patient who received SHINGRIX for prophylaxis. On 27th April 2018, the patient received the 1st dose of SHINGRIX .5 ml. On 28th April 2018, 1 days after receiving SHINGRIX, the patient experienced rash and pain burning. The patient was treated with VALTREX. SHINGRIX was discontinued. On an unknown date, the outcome of the rash and pain burning were not recovered/not resolved. The reporter considered the rash and pain burning to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported but it could be 88 years or 89 years. Next day after SHINGRIX dose, the patient experienced rash and burning pain. These event continued to get worse so the patient visited physician on 2nd May 2018. As per physician the symptoms were consistent to herpes simplex and started patient on VALTREX. The culture test was negative so they associated rash and burning pain with vaccine. The patient chose not to get 2nd dose of vaccine.
One week after 3rd Imovax, the patient had dizziness, fever, nausea, diarrhea, bloating, and malaise for 4 days.
Polyarthralgia in hips, knees, shoulders and elbow with moderate severity for 3 days and minimal severity for 3 additional days. Patient used Motrin for pain, which helped mildly.
Dark pink area roughly the size of her hand to her left arm from the shoulder extending down below the vaccination site. Patient reports area smooth, not raised, no itching, no pain with slight warmth to the area.
Patient received vaccine and while waiting his 15 minutes he reported feeling dizzy and was sweating. The nurse called for the EMTs and they took him in hall to take his vitals. His HR was in the 40s to 50s so they did an EKG. He has a history of heart disease and had an ablation  about a year ago. The paramedics took him to a nearby hospital.
soreness at the injection site; developed redness; rash in left arm going down to elbow; reports her arm is hot; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 68-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 05-JUN-2023, the patient received the 1st dose of Shingrix (left arm). On 07-JUN-2023, 2 days after receiving Shingrix, the patient experienced injection site pain (Verbatim: soreness at the injection site), injection site erythema (Verbatim: developed redness), rash (Verbatim: rash in left arm going down to elbow) and hot feeling in hand (Verbatim: reports her arm is hot). The outcome of the injection site pain, injection site erythema, rash and hot feeling in hand were unknown.   It was unknown if the reporter considered the injection site pain, injection site erythema, rash and hot feeling in hand to be related to Shingrix.     It was unknown if the company considered the injection site pain, injection site erythema, rash and hot feeling in hand to be related to Shingrix.   Additional Information: GSK Receipt Date: 07-JUN-2023 The reporter reported that the patient received Shingrix and on day of reporting, she developed redness and soreness at the injection site, also reported her arm was hot and a rash in left arm went down to elbow.   Adverse Event was filed. The patient stated she had medical attention for that matter and was prescribed prednisone and antibiotics. The reporter consented to follow up.
Localized redness, headache, severe pain in arm, flu like symptoms. Told them of previous sensitivity to DTP as child. Asked for plain Tetanus, they accidentally gave me D-TaP pediatric dose!
Low grade temp facial puffiness and redness on the 28th, on the 29th rash over body, puffy red eyes, fever OTC Benadryl.
entire arm including hand hurt; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (entire arm including hand hurt) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (entire arm including hand hurt). At the time of the report, PAIN IN EXTREMITY (entire arm including hand hurt) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant Drug details were reported.  No Treatment information was provided.
See prior notes.  Patient went to the clinic because he thought that he pulled a muscle in his shoulder while lifting a case of water.  Doctor diagnosed it as a pulled muscle and told him to ice it.  Over the next few days the pain moved to his other shoulder and his neck.  On May 5 he slid to the floor and fireman were called to put him into bed at home.  On the morning of May 6, he was still in pain and called the clinic.  They told him to go to the emergency room at the nearest hospital because his blood work on 5/2 showed low kidney function.  On May 6 or 7 he had a cardiac arrest and seizures.  He was put on a ventilator.  Pneumonia was suspected.  He was in ICU until May 10 or 11.  His health went downhill thereafter and he died on May 18 he died.
Pt "blacked out" & legs went stiff shortly (within 5 mins of receiving vaccination), pt reported feeling cold & seeing black spots, emergency personnel was called immediately, water was given & monitored until emergency personnel arrived on site. Patient reported waves of feeling better & worse throughout the course of waiting for emergency personnel. Emergency personnel evaluated patient & transported to local hospital.
Service member experienced fever (>100 degrees), difficulty going to sleep, body aches, fatigue and cellulitis (10 cm x 15 cm area surrounding smallpox vaccine site in right arm with redness, warmth, and tenderness, as well as swollen axillary lymph nodes) with most symptoms lasting about one week .
tired from loss of sleep; nose was dripping; acid reflux/ it was worse than before; pretty sick; throwing up; loss of sleep; lightheaded and dizzy; She experienced soreness on her arm after the first shot; This is a spontaneous report from a contactable consumer (patient). An 84-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in arm left on 10Mar2021 14:30 (Batch/Lot Number: EL9269) as 1st dose, single for covid-19 immunisation. Medical history included  ongoing shingles (but got the shot anyway), ongoing acid reflux (been years and years and years ago, way back in 1990s or so maybe later than that), high blood pressure from 2001 and ongoing, dry eye, macular degeneration, CPO because she was a smoker, 4 bypass surgery, allergic to a blood pressure medicine, blood thinner therapy, and bad sinuses. Concomitant medications included calcium carbonate, magnesium carbonate (TUMS) taken for gastrooesophageal reflux disease, start and stop date were not reported; amlodipine taken for hypertension from 2001 and ongoing; albuterol sulfate taken for ex-tobacco user, pulmonary oedema, start and stop date were not reported; krill oil taken for an unspecified indication, start and stop date were not reported; cetirizine hydrochloride (ZYRTEC) taken for hypersensitivity, start and stop date were not reported; aspirin taken for anticoagulant therapy, start and stop date were not reported; ciclosporin (RESTASIS) taken for dry eye, start and stop date were not reported. She experienced soreness on her arm after the first shot. Patient have acid reflux anyway and it seemed like it come up and it was worse than before, she was pretty sick last night on 15Mar2021 throwing up and still feeling pretty bad today from loss of sleep. Her nose was dripping and her head was all lightheaded, was dizzy and she was sick to her stomach. She sat in her recliner until about 3AM. Patient did not know if this was from the shot or what, but it was terrible. These things were not really ongoing on 16Mar2021, but she feels tired on 16Mar2021 from the loss of sleep on 15Mar2021. She took her antihistamine and her blood pressure pills and she was alright now, just tired from no rest. She reported that she was scheduled for her second dose of the product on 31Mar2021 at 150PM. Patient had blood work done at her last physical on 20Jan2020, and she reports that was all good. Outcome of the events was unknown.
Client developed a rash on back arms and chest.  Client stated there was over 50 dots on the child's back alone.  They are not raised, but flat purple color dots that are nearly the size of a dime the mother explained.  The client has also been itching for 2 days previous to this rash but child has history of eczema. Client has no fever and is behaving as normal otherwise.
Below 18 years age female patient received 1st dose; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Below 18 years age female patient received 1st dose) in a 16-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Below 18 years age female patient received 1st dose). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Below 18 years age female patient received 1st dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The concomitant medications were not provided. The treatment medications were not provided.
First injection of the hepatitis B vaccine series given to individual by employee health nurse. Vaccine offered by employer, she works in a Long Term Care facility. Immediately after the injection, individual felt a light numbness in the right upper arm, from the elbow to the shoulder. She also felt pain in the arm, radiating to the right shoulder blade. She is still having pain in the arm and shoulder blade when she moves it, especially when moving arm above head and while lying on the arm.
Sluggish; It felt like a bully at school.; Soreness in arm; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (Sluggish), FEELING ABNORMAL (It felt like a bully at school.) and PAIN IN EXTREMITY (Soreness in arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-May-2021, the patient experienced LETHARGY (Sluggish), FEELING ABNORMAL (It felt like a bully at school.) and PAIN IN EXTREMITY (Soreness in arm). At the time of the report, LETHARGY (Sluggish), FEELING ABNORMAL (It felt like a bully at school.) and PAIN IN EXTREMITY (Soreness in arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product details was not provided by the reporter. Treatment information was not provided.    Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Follow up document contains No new information On 27-Jul-2021: TCR : Follow up document contains No New Information
No data provided. 60 day follow-up states the pt has seizures. Discharge summary states diagnosis is shaken baby syndrome,inferior vena cava thrombus. Per F/U 8/9/01: Hypertonicity; right visual defect/deficit and Shaken Baby Syndrome resulting in seizure disorder and visual problems. Pt had PEG placed 12/00 secondary to feeding intolerance. Pt now in foster care since January. Foster mother reports steady weight gain and has not used the G-tube for about 9 weeks. After consultation, foster mother requested G-tube removal. Discharge DX: Shaken Baby Syndrome; Inferior vena cava thrombus; vision impairment; hearing impairment; reflux; S/P fungemia (Candida) and also VRE bacteremia; respiratory distress
SLE; inflammatory infectious changes in her brain and 20 to 25 lesions on her brain; migraine headache syndrome; vasculitis; shingles; Information has been received from a lawyer regarding a case in litigation concerning a female patient(pt) of unknown age. The pt's medical history, concurrent conditions and concomitant medications were not provided. On 11-FEB-2016, the pt was vaccinated with zoster vaccine live(ZOSTAVAX) at a physician office for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). In approximately April 2016 (reported as "within two to three months of receiving zoster vaccine live(ZOSTAVAX)"), pt suffered severe and debilitating shingles, rashes and severe headaches and was subsequently diagnosed with migraine headache syndrome, vasculitis and systemic lupus erythematosus(SLE) due to inflammatory infectious changes in her brain and 20 to 25 lesions on her brain. All of these injuries were caused by zoster vaccine live(ZOSTAVAX). These symptoms and injuries remain today. As a direct and proximate result of zoster vaccine live(ZOSTAVAX), pt's symptoms have resulted in physical limitations not present prior to using zoster vaccine live(ZOSTAVAX) and caused by the zoster vaccine live(ZOSTAVAX). Pt also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of zoster vaccine live(ZOSTAVAX), pt sustained severe and debilitating personal injuries. Further, as a tragic consequence of zoster vaccine live(ZOSTAVAX), pt suffered serious, progressive, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live(ZOSTAVAX), pt has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages.  Upon internal review, systemic lupus erythematosus due to inflammatory infectious changes in her brain and 20 to 25 lesions on her brain were determined to be medically significant. The events shingles, migraine headache syndrome, vasculitis and SLE due to inflammatory infectious changes in her brain and 20 to 25 lesions on her brain were considered as disability.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 1:52 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 1:52 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 68.64 for dose administered on 07-Jan-2021. No concomitant medications were reported. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34 or 35 degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.
My body is sore and stiff all over, chills and hot hours after getting the vaccine.
Information has been received from a physician concerning a 47 month old Caucasian male patient with a medical history of RAD who on 3/27/00, (previously reported as 3/27/02) was vaccinated with a SC first dose in the left thigh of varicella virus vaccine live (lot number 632054/1447J). Illnesses at the time of vaccination were a URI and conjunctivitis. Concomitant therapy on 3/27/00, (previously reported as 3/27/02) included a SC first dose in the right thigh of MMR (lot number 634040/1715J). On 3/11/03 in the AM, the patient developed chicken pox described as a rash with 12-15 red papular lesions which never really vasiculated or crusted, and the patient had no fever. There was no relevant diagnostic laboratory data. It was als noted that the child was at the physician's office and was clinically diagnosed with croup, also described as URI/Croup-like illness, 48 hours prior to eruption. Unspecified medical attention was sought. On 3/14/03, the patient recovered. There was no product quality complaint involved. The physician also reported on two other siblings that developed chicken pox. No further information is expected.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On an unknown date in 2015, a pharmacist at a pharmacy administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On an unknown date in 2015, the patient was treated by a healthcare provider at an urgent care facility for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of her injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Received 2nd dose of Lymes vaccine and within an hour, developed fever, chills, malaise, dizziness and he felt like he would faint. This lasted until around 08:00 the next morning. Also, had redness around area of injection.
On 01/17/2001 the patient developed the "worst case" of chicken pox that the physician had ever seen in an immunized child. The child had pox all over her face, trunk, arms, legs, scalp and mucous membrane. The patient was treated with Benadryl. Additional information has been requested.
Post menopause bleeding; This is a spontaneous report from a contactable consumer (Patient). A 55-year-old non-pregnant female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Right on 15Mar2021 (Batch/Lot Number: EP7534) as single dose for covid-19 immunisation at the age of 55-year-old. Medical history included ongoing high blood pressure, Allergies shrimps. Concomitant medications included lisinopril and lovastatin. The patient experienced post menopause bleeding on 19May2021 with outcome of not recovered. No treatment received for the event. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine, was not diagnosed with COVID-19 prior to vaccination and hasn't been tested for COVID-19 since the vaccination.  Information about lot/batch number was available. Additional information has been requested.
Hives - began around 6pm on 4/28/09 started on her face, 4-29-09 in morning woke up with all over still with hives today 4-30-09 has had 5 doses of benadryl eyrtec recommended at office.
Influenza/COVID-19 Nucleic Acid Amplification Test performed on 7/16/21 at 07:45. Result came back positive. Case investigation interview with patient has not been conducted as of the time of this written note.
Got the shot in the morning - no reaction other than sore arm which was normal. Later around 3pm, started becoming more tired so I took 6h nap. Woke up around 9, mostly just laying in bed. Started getting chills so I took a shower at 11, go out and started to feel nauseous. Went to restroom feeling like I was gonna vomit. I fainted instead.. for maybe 20-30 seconds I was out? Not sure since I was alone. Chills intensified to my whole body shaking pretty violently- I couldnt even point straight without looking like a Grimm Reaper! I was helped back into bed by my father and slowly fell asleep. This morning I still have some jitters but much less so - but my head is killing me.